Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. The company's strategy includes leveraging partnerships with a therapeutic focus geared toward developing a broad portfolio of pipeline candidates. The company also targets autoimmune disorders and infectious diseases. The company's intellectual property is characterized by its patent use to protect the composition of its product candidates and the technology used to create them.
Quote | MacroGenics Inc. (NASDAQ:MGNX)
Last: | $5.40 |
---|---|
Change Percent: | -2.7% |
Open: | $5.55 |
Close: | $5.55 |
High: | $5.605 |
Low: | $5.36 |
Volume: | 346,463 |
Last Trade Date Time: | 07/29/2024 03:00:00 am |
News | MacroGenics Inc. (NASDAQ:MGNX)
2024-07-29 07:15:06 ET Barclays analyst issues OVERWEIGHT recommendation for MGNX on July 29, 2024 05:41AM ET. The previous analyst recommendation was Overweight. MGNX was trading at $5.55 at issue of the analyst recommendation. The overall analyst consensus : BUY. C...
2024-07-29 07:00:10 ET Peter Lawson from Barclays issued a price target of $9.00 for MGNX on 2024-07-29 05:41:00. The adjusted price target was set to $9.00. At the time of the announcement, MGNX was trading at $5.55. The overall price target consensus is at $15.43 with ...
Message Board Posts | MacroGenics Inc. (NASDAQ:MGNX)
Subject | By | Source | When |
---|---|---|---|
whytestocks: $MGNX News Article - Why Shares of MacroGenics Climbed Thursday | whytestocks | investorshangout | 03/16/2023 4:35:50 PM |
Historic short interest: | XenaLives | investorshub | 01/31/2023 7:02:57 PM |
So what exactly did $MGNX do to this | XenaLives | investorshub | 12/15/2022 12:42:06 AM |
Looking at $MGNX because the chart is intriguing.. | XenaLives | investorshub | 12/15/2022 12:38:51 AM |
Now I need to figure out what DART | XenaLives | investorshub | 12/15/2022 12:35:41 AM |
News, Short Squeeze, Breakout and More Instantly...
2024-07-29 07:15:06 ET Barclays analyst issues OVERWEIGHT recommendation for MGNX on July 29, 2024 05:41AM ET. The previous analyst recommendation was Overweight. MGNX was trading at $5.55 at issue of the analyst recommendation. The overall analyst consensus : BUY. C...
2024-07-29 07:00:10 ET Peter Lawson from Barclays issued a price target of $9.00 for MGNX on 2024-07-29 05:41:00. The adjusted price target was set to $9.00. At the time of the announcement, MGNX was trading at $5.55. The overall price target consensus is at $15.43 with ...
MacroGenics, Inc. (NASDAQ: MGNX) is the focus of IBN's latest stock spotlight. The company's shares have moved 1.9% on the day to $5.35. MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved pr...